To identify the superbug, the firm used a rapid test that assigns microbial DNA fingerprints to reveal the clonal identity of a bacterial strain in patient samples.
The newly emerged Nashville Biosciences has the considerable genomics and bioinformatics resources of Vanderbilt behind it as it promotes new R&D techniques.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
The developers said that their multivariant analysis does a better job than using APOE E4 alone at identifying those at greatest risk of developing Alzheimer's.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.
